SCHEMBL13554

SCHEMBL13554

CC(F)(F)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
TSHR P16473 2/20 0.58
MAPK1 P28482 1/20 0.50
TAAR1 Q96RJ0 1/20 0.46
ALOX15 P16050 1/20 0.46
ESR1 P03372 2/20 0.44
ESR2 Q92731 2/20 0.44
PTPN1 P18031 1/20 0.44
CYP3A4 P08684 1/20 0.44
KCNN4 O15554 3/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA5A P35218 1/20 0.42
CA9 Q16790 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
KIF11 P52732 1/20 0.42
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
CYP2B6 P20813 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6342232 1.00 ALDH1A1 (0.58) ALDH1A1TSHRMAPK1TAAR1ALOX15
SCHEMBL10910918 0.85 MAPT (0.48) ALDH1A1TSHRMAPK1ALOX15ESR1
SCHEMBL17035905 0.84 KIF11 (0.65) ALDH1A1TSHRMAPK1TAAR1PTPN1
SCHEMBL12299036 0.83 TSHR (0.40) ALDH1A1TSHRESR1ESR2CYP3A4
SCHEMBL3621303 0.81 ALDH1A1 (0.58) ALDH1A1TSHRMAPK1TAAR1ALOX15
SCHEMBL17885872 0.81 ALDH1A1 (0.58) ALDH1A1TSHRMAPK1TAAR1ALOX15
SCHEMBL23789538 0.79 ALDH1A1 (0.55) ALDH1A1TSHRMAPK1TAAR1ALOX15
SCHEMBL10430589 0.79 ALDH1A1 (0.55) ALDH1A1TSHRMAPK1TAAR1ALOX15
SCHEMBL9350826 0.79 ALDH1A1 (0.55) ALDH1A1TSHRMAPK1TAAR1ALOX15
SCHEMBL15372301 0.78 LTA4H (0.52) ALDH1A1TSHRMAPK1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112794955-A Low-water-absorption polyimide resin and preparation method thereof 长沙新材料产业研究院有限公司 2021-05-14 CN claimed
US-20040192930-A1 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation G.D. SEARLE & CO. (US) 2004-09-30 US claimed
EP-0923933-B1 Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation SEARLE & CO (US) 2002-07-03 EP claimed
EP-0923933-A1 Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation G.D. SEARLE & CO. (US) 1999-06-23 EP claimed
EP-0854723-A1 SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS G.D. SEARLE & CO. (US) 1998-07-29 EP claimed
WO-1997011704-A1 SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS G.D. SEARLE & CO. (US) 1997-04-03 WO claimed
EP-0731795-A1 SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-09-18 EP claimed
WO-1995015316-A1 SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION G. D. SEARLE & CO. (US) 1995-06-08 WO claimed
EP-3527600-B1 ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER ASAHI CHEMICAL IND (JP) 2025-07-09 EP disclosed
CN-119751366-A Dual-mechanism deep fungal infection resistant medicament 上海友长医药有限公司 2025-04-04 CN disclosed
CN-119431313-A Antifungal compound, preparation method and application thereof 上海交通大学 2025-02-14 CN disclosed
EP-4309741-A1 CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-01-24 EP disclosed
US-20230399287-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2023-12-14 US disclosed
EP-4275759-A2 QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER Dana-Farber Cancer Institute, Inc. (US) 2023-11-15 EP disclosed
US-5313001-A Reacting a halogenated aromatic compound with a 1,1-difluoro ethylene compound in presence of palladium catalyst HOECHST AKTIENGESELLSCHAFT (DE) 1994-05-17 US disclosed
EP-0530208-A1 PROCESS FOR PRODUCING ALPHA-FLUOROSTYROLS HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-10 EP disclosed
WO-1991016286-A1 PROCESS FOR PRODUCING α-FLUOROSTYROLS HOECHST AKTIENGESELLSCHAFT (DE) 1991-10-31 WO disclosed
US-4668830-A Process for the preparation of compounds containing a difluoromethylene or trifluoromethyl group RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1987-05-26 US disclosed
US-4001406-A BENZENEDISULFONAMIDES AS ANTHELMINTIC AGENTS MERCK & CO., INC. (US) 1977-01-04 US disclosed
US-3976691-A Dialkylaminosulfur trifluorides as fluorinating agents E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192930-A1 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation IL6, HRH4, CCR2 ALDH1A1 1964/4885TSHR 1806/4885MAPK1 1946/4885
US-20230399287-A1 NOVEL COMPOUNDS CNKSR1, RORC, HLA-DRB1 ALDH1A1 182/4885TSHR 1689/4885MAPK1 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.